Rznomics announced that it is joining Lilly Gateway Labs (LGL) in San Diego, California.

Lilly Gateway Labs is a best-in-class innovation hub designed to empower biotechnology companies to advance groundbreaking science by providing access to wet lab facilities and opportunities to engage with Lilly scientists and executives.

Lilly Gateway Labs is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly ExploR&D, and Lilly TuneLab, which together support biotech innovation by providing access to strategic capital, lab space and technology, and research and development (R&D) capabilities.

Through its entry into Lilly Gateway Labs, Rznomics plans to accelerate candidate discovery and development across its target gene database bank comprising over 200 disease targets, while simultaneously driving long-term efforts to establish global clinical infrastructure for its lead pipelines, expand global strategic partnerships, and recruit top-tier R&D researchers in the US.

Seong-Wook Lee, CEO, Rznomics, said, "Joining Lilly Gateway Labs in San Diego represents a meaningful milestone for Rznomics' proprietary RNA platform.We intend to advance the development and commercialisation of our RNA therapeutics by active collaboration with the global biotech ecosystem."